Abcuro has collected $66 million a few months after saying its sole drug missed the mark in inclusion body myositis, but had found hope in a subset of patients with less severe forms.
August 14, 2026 11:28 AM EDT
Abcuro gets $66M for Phase 3 in muscle-weakening condition
Abcuro has collected $66 million a few months after saying its sole drug missed the mark in a muscle-weakening condition but had found hope in …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
AbCellera raises $200M after Phase 2 win; Silence Therapeutics raises $175M post-Phase 2 success in rare blood cancer; InduPro…
Angitia halts a Phase 3 disc-disease trial, Abivax prices an upsized $800M offering, and AlzeCure lands a $2.2B NeuroRestore deal…
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Abivax says new Phase 3 data show cancer rates within expected range for its UC drug obefazimod, though Jefferies flags lingering…
AbCellera's $ABCL surged 38% after ABCL635 cut hot flash frequency 50% over placebo in Phase 2, outperforming Astellas' Veozah…
